Evaluation of dendronized gold nanoparticles as siRNAs carriers into cancer cells

Gene therapy is one of the most promising approaches for potential application in the treatment of diseases, ranging from cancer and heritable disorders to infectious diseases. Before nucleic acid molecules can reach their site of action inside target cells, they must overcome several obstacles. Thus, to fully exploit the therapeutic potential of nucleic acids, efficient delivery systems are required. We herein evaluated gold nanoparticles (AuNPs) covered with cationic carbosilane dendrons as siRNA delivery systems. Detailed analysis of formation of AuNP:siRNA complexes using circular dichroism, zeta-potential, zeta-size, electron microscopy and gel electrophoresis was performed. The stability of complexes in presence of heparin and RNase was evaluated. Internalization of AuNPs and their complexes with siRNAs into cancer cells was estimated by ultrastructure analysis and confocal microscopy. The cytotoxicity of dendrons, AuNPs and their complexes with siRNAs on 4 cancer cell lines (Caco-2, HeLa, U937 and THP-1) was estimated. We concluded that dendronization of AuNPs is a promising way to develop siRNA carriers for anticancer gene therapyUniversidad de AlcaláMinisterio de Economía y CompetitividadComunidad de MadridJunta de Comunidades de Castilla-La ManchaEuropean Commissio

Ruthenium Dendrimers against Human Lymphoblastic Leukemia 1301 Cells

Ruthenium atoms located in the surfaces of carbosilane dendrimers markedly increase their anti-tumor properties. Carbosilane dendrimers have been widely studied as carriers of drugs and genes owing to such characteristic features as monodispersity, stability, and multivalence. The presence of ruthenium in the dendrimer structure enhances their successful use in anti-cancer therapy. In this paper, the activity of dendrimers of generation 1 and 2 against 1301 cells was evaluated using Transmission Electron Microscopy, comet assay and Real Time PCR techniques. Additionally, the level of reactive oxygen species (ROS) and changes of mitochondrial potential values were assessed. The results of the present study show that ruthenium dendrimers significantly decrease the viability of leukemia cells (1301) but show low toxicity to non-cancer cells (peripheral blood mononuclear cells—PBMCs). The in vitro test results indicate that the dendrimers injure the 1301 leukemia cells via the apoptosis pathway.Funding: This work was co-financed by the Project EUROPARTNER of Polish National Agency for Academic Exchange (NAWA) and Pl-SK 2019–2020 bilateral project -PPN/BIL/2018/1/00150; supported by the project “NanoTENDO” granted by National Science Centre, Poland under the M-ERA.NET 2 of Horizon 2020 programme, project No: 685451. This research was also supported by grants from CTQ2017-86224-P (MINECO), consortiums IMMUNOTHERCAN-CM B2017/BMD-3733, NANODENDMED II-CM ref B2017/BMD-3703 and Project SBPLY/17/180501/000358 Junta de Comunidades de Castilla-La Mancha (JCCM). CIBER-BBN is an initiative funded by the VI National R&D&I Plan 2008–2011, IniciativaIngenio 2010, Consolider Program, CIBER Actions and financed by the Instituto de Salud Carlos III with assistance from the European Regional Development Fund. Acknowledgments: N.S.d.O. wishes to thank JCCM for a predoctoral fellowship. This article is based upon work from COST Action CA17140 “Cancer Nanomedicine from the Bench to the Bedside” supported by COST(European Cooperation in Science and Technology)

Circulating microRNAs in Medicine

Circulating microRNAs (c-microRNAs, c-miRNAs), which are present in almost all biological fluids, are promising sensitive biomarkers for various diseases (oncological and cardiovascular diseases, neurodegenerative pathologies, etc.), and their signatures accurately reflect the state of the body. Studies of the expression of microRNA markers show that they can enable a wide range of diseases to be diagnosed before clinical symptoms are manifested, and they can help to assess a patient’s response to therapy in order to correct and personalize treatments. This review discusses the latest trends in the uses of miRNAs for diagnosing and treating various diseases, viral and non-viral. It is concluded that exogenous microRNAs can be used as high-precision therapeutic agents for these purposes

Engineered phosphorus dendrimers as powerful non-viral nanoplatforms for gene delivery: a great hope for the future of cancer therapeutics

International audienceDuring the past two decades, tremendous progress has been made in the dendrimer-based delivery of therapeutic molecules including, for instance, small molecules, macromolecules, and genes. This review deals with recent successes in the development of promising biocompatible phosphorus dendrimers, a specific type of dendrimer, to deliver genes to treat cancers

Phosphorus dendrimers as powerful nanoplatforms for drug delivery, as fluorescent probes and for liposome interaction studies: A concise overview

International audienceGene therapy is a new and promising tool to treat many severe diseases and the silencing of proteins is the safest and the most efficient tool to treat diseases because it does not induce changes in human genome and avoids a huge problem encompassing insertional mutagenesis. Using small RNAs to switch on/off target proteins is limited due to existence of some barriers for them in the human body (blood RNAses, serum albumins, cell walls, etc). For therapeutic applications they need the efficient and non-toxic carrier which will deliver them into cell cytoplasm. Within the huge range of carriers available, dendrimers can be underlined as new promising efficient carriers. This review summarizes several findings in phosphorus dendrimers based on in vitro and in vivo studies. As a result, we can conclude that advantages of phosphorus dendrimers are strong interaction with siRNA/DNA and formation of small and compact positively charged complexes of high and fast penetration into cells; efficient release of siRNA/pDNA in endosomes due to “proton sponge” effect; possibility of their modification including addition of fluorescent probes - in this case fluorescent dendrimer can be used both as a gene carrier and a tracer of delivery into cells. Additional benefit of using fluorescent phosphorus dendrimers is their ability to monitor the macrophage physiological status in vitro and in vivo

Phosphorus-containing nanoparticles: biomedical patents review

International audienceIn the present review, we have analyzed the patents on phosphorus-based nanomaterials (fullerenes, quantum dots [QDs], graphene, liposomes, dendrimers, gold and silver NPs) in biology and medicine. Their impact in treatment of cancer, viral infections and cardiovascular diseases is discussed

Dendrimers Show Promise for siRNA and microRNA Therapeutics

The lack of an appropriate intracellular delivery system for therapeutic nucleic acids (TNAs) is a major problem in molecular biology, biotechnology, and medicine. A relatively new class of highly symmetrical hyperbranched polymers, called dendrimers, shows promise for transporting small TNAs into both cells and target tissues. Dendrimers have intrinsic advantages for this purpose: their physico-chemical and biological properties can be controlled during synthesis, and they are able to transport large numbers of TNA molecules that can specifically suppress the expression of single or multiple targeted genes. Numerous chemical modifications of dendrimers extend the biocompatibility of synthetic materials and allow targeted vectors to be designed for particular therapeutic purposes. This review summarizes the latest experimental data and trends in the medical application of various types of dendrimers and dendrimer-based nanoconstructions as delivery systems for short small interfering RNAs (siRNAs) and microRNAs at the cell and organism levels. It provides an overview of the structural features of dendrimers, indicating their advantages over other types of TNA transporters